ICU Medical, Inc. cash flow to debt ratio of 12.92% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

ICU Medical, Inc.'s free cash flow has decreased -26.36% from $124.66M last year to $91.80M, signaling decreasing performance

ICU Medical, Inc.'s debt to equity ratio is 0.64, which means that the company's assets are unhealthy financed, signaling financial risk. READ MORE: A ratio over 0.60 means the company finances its assets with debt, signaling financial risk. If ratio is negative, the company spent its own equity and risks bankruptcy

ICU Medical, Inc.'s debt has decreased relative to shareholder equity from 0.84 last year to 0.64 today, signaling strengthened financials

ICU Medical, Inc. has a net debt to EBITDA ratio of 3.32x, which exceeds the 3.00x threshold, indicating high leverage and potential financial risk

ICU Medical, Inc.'s interest coverage ratio is 0.92, which means that the company struggles to meet interest obligations, signaling financial risk.

ICU Medical, Inc.'s profit margin has increased (-143.49%) in the last year from -4.94% to 2.15%, signaling increasing performance

ICU Medical, Inc.'s short-term assets of $1.18G exceed its short-term liabilities of $498.86M

ICU Medical, Inc.'s return on assets of 1.15% is lower than the 5.00% threshold, indicating inefficient asset utilization

ICU Medical, Inc.'s return on equity of 2.19%, is lower than 15.00%, indicating bad performance

ICU Medical, Inc.'s operating cash flow exceeds its net income, indicating high-quality earnings backed by actual cash generation

ICU Medical, Inc. had positive net income in only 2.00 out of 5 years, indicating unstable earnings

ICU Medical, Inc. has positive free cash flow, indicating the company generates cash after capital expenditures

ICU Medical, Inc. has a free cash flow yield of 2.39%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

ICU Medical, Inc.'s yearly earnings has increased -100.62% since last year from $-117.69M to $732.00K, signaling increasing performance

ICU Medical, Inc.'s yearly revenue has decreased -6.38% since last year from $2.38G to $2.23G, signaling decreasing performance

ROIC 2.27% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

ICU Medical, Inc.'s 3-year revenue CAGR of -0.74% is negative, indicating declining revenue over the past 3 years

ICU Medical, Inc. had revenue growth in 3.00 out of 5 years, indicating consistent revenue performance

ICU Medical, Inc. had positive ROE in only 2.00 out of 5 years, indicating inconsistent returns on equity

ICU Medical, Inc. has insufficient data to evaluate this check.

ICU Medical, Inc. has an earnings yield of 1.22%, which is below the 4.00% threshold, indicating the stock may be expensive relative to its earnings

ICU Medical, Inc. is overvalued relative to its fair value price of 48.08 based on EBITDA multiple model

ICU Medical, Inc. has an EV/EBITDA ratio of 15.07x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings

ICU Medical, Inc. is overvalued relative to its fair value price of 3.60 based on Earnings Fair Value model

ICU Medical, Inc. has a PEG-ratio under 1 which is considered undervalued

ICU Medical, Inc. has a price-to-book ratio of 1.80x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

ICU Medical, Inc. has a price-to-sales ratio of 1.76x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue